Product Description
Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. Consequently, nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and cancerous prostatic tissue. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8453188/)
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Chile | Colombia | France | India | Mexico | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | Sweden | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|